Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$2.04 USD
-0.06 (-2.86%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.05 +0.01 (0.49%) 4:26 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRBU 2.04 -0.06(-2.86%)
Will CRBU be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRBU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRBU
Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates
Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know
CRBU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
Will Caribou Biosciences, Inc. (CRBU) Report Negative Q1 Earnings? What You Should Know
Other News for CRBU
Caribou Biosciences: Key Data Updates Coming, But I'm Concerned About Near-Term Volatility
Caribou Biosciences Regains Nasdaq Compliance
Caribou Biosciences Confirms Director Elections and Auditor
Bank of America Securities Reaffirms Their Buy Rating on Caribou Biosciences (CRBU)
Caribou Biosciences (CRBU) Receives a Hold from Evercore ISI